QuidelOrtho Corporation reports developments in in vitro diagnostics, including rapid testing, immunoassay and molecular testing, clinical chemistry, transfusion medicine and point-of-care diagnostic platforms. Company updates commonly address financial results, revenue trends, guidance, respiratory testing seasonality, international market conditions and portfolio activity across labs, cardiac, immunohematology and molecular diagnostics.
Recurring news also covers product and technology developments such as the LEX VELO System, a point-of-care molecular PCR platform with FDA 510(k) clearance and CLIA waived status for Flu A, Flu B and COVID-19 testing, as well as diagnostic education topics including syphilis screening and high-sensitivity troponin. Governance and management changes appear alongside business updates and investor conference participation.
QuidelOrtho (QDEL) reported third-quarter revenue of $618.9 million, down 12% year over year, and lowered its full-year guidance ceilings. For the quarter ended September 27, 2026, GAAP net loss narrowed to $53.8 million, or $0.78 per diluted share, from $733.0 million. Adjusted diluted earnings fell to $0.31 from $0.80, while adjusted EBITDA, an adjusted earnings measure, declined to $148.0 million from $177.1 million.
Labs sales declined amid China pricing changes, and Point of Care sales fell with a softer respiratory season. Operating cash flow improved to $19.6 million from negative $45.5 million. QuidelOrtho expects its new restructuring program to deliver over $80 million in annual savings in 2027, with approximately $30–$35 million in fourth-quarter 2026 charges. Updated 2026 guidance calls for revenue of $2.52–$2.54 billion and adjusted diluted earnings of $0.65–$0.70 per share.
QuidelOrtho (QDEL) has released episode 62 of its Science Bytes podcast, exploring AI and informatics in laboratory operations. Hosted by Josh Casey, the episode features Rodney Guzman, the company's vice president of software engineering for global informatics platforms.
The discussion examines how informatics can organize data from separate laboratory systems. It presents standardized, reliable and traceable data as a prerequisite for reliable AI insights and discusses applications in transfusion medicine. The episode describes AI as supporting clinical experts, with laboratory professionals retaining responsibility for interpreting results and making final decisions.
QuidelOrtho (Nasdaq: QDEL) will report its third-quarter 2026 financial results after the market closes on November 3, 2026. The quarter ended September 27, 2026. A conference call and webcast will follow at 5:00 p.m. ET / 2:00 p.m. PT, with a replay available afterward on the company's website.
QuidelOrtho (QDEL) granted equity awards covering 50,323 common shares to two newly hired, non-executive employees as employment inducements.
The awards consist of restricted stock units (RSUs), granted on October 15, 2026, under the 2026 Inducement Plan. They vest in equal annual installments on the first three anniversaries of the grant date, subject to continued employment through each vesting date. The board's Compensation Committee approved the grants in accordance with Nasdaq Listing Rule 5635(c)(4).
QuidelOrtho (QDEL) appointed Sanjeev Sharma as Vice President of Investor Relations, effective September 28, 2026, bringing experience in investor relations and strategy.
Sharma has more than 20 years of experience across investor relations, corporate strategy and equity research. He most recently served as Senior Director of Investor Relations at Teva Pharmaceuticals. Previously, he spent more than a decade at Genpact and nearly six years in sell-side equity research. He holds a master's degree in finance and is a Chartered Financial Analyst.
QuidelOrtho (QDEL) highlighted episode 61 of its Science Bytes podcast on September 24, 2026, focusing on sepsis diagnosis in emergency care.
Hosted by Josh Casey, the episode features medical science liaison Chris Sanchez discussing early testing and the difficulty of distinguishing bacterial from viral infections. It also covers serial procalcitonin testing, which measures a blood marker over time, to help clinicians identify when antibiotics may be stopped or reduced.
QuidelOrtho (Nasdaq: QDEL) released episode 60 of its Science Bytes podcast, highlighting key themes from the 2026 Association for Diagnostics and Laboratory Medicine (ADLM) Annual Conference. Host Stephanie Kleewein speaks with experts from LEX Diagnostics, Thermo Fisher Scientific and QuidelOrtho about innovations in molecular diagnostics, antibiotic stewardship and cardiovascular assessment.
Key insights include ultra-fast RT-PCR delivering respiratory results in as little as six minutes, simplified workflows that support near-patient and CLIA‑waived molecular testing, the use of procalcitonin (PCT) to guide antibiotic use with reported reductions in antibiotic exposure and adverse events, and high-sensitivity troponin testing to speed evaluation of suspected cardiac events. According to QuidelOrtho, these advances aim to give clinicians rapid, actionable information to improve emergency department flow, decision-making and patient outcomes.
QuidelOrtho (Nasdaq: QDEL) reported second quarter 2026 total revenue of $630.9 million, up 3% reported and 2% in constant currency, with revenue excluding China up 6%. Labs revenue was $382.9 million (+3.6% reported), Immunohematology $134.2 million (+1.4%), and Point of Care $108.2 million (+16.3%).
The company recorded a GAAP net loss of $92.9 million (diluted loss per share $1.36) and GAAP operating loss of $21.8 million, while adjusted EBITDA reached $129.3 million with a 20.5% margin, up 310 basis points. China revenue declined 18.7% to $67.8 million; revenues excluding China were $563.1 million, up 6.1%.
QuidelOrtho cut its full‑year 2026 guidance, now expecting reported revenue of $2.52–$2.60 billion (from $2.70–$2.75 billion), adjusted EBITDA of $540–$560 million (margin 21–22%), and adjusted diluted EPS of $0.65–$0.90. The company also withdrew prior free cash flow guidance of $100–$120 million.
QuidelOrtho (Nasdaq: QDEL) announced it will report financial results for its second quarter 2026, ended June 28, 2026, after the market close on Thursday, August 6, 2026. A conference call to discuss the results will begin at 2:00 p.m. PT / 5:00 p.m. ET, accessible via the Events & Presentations section of the Investor Relations page on the company’s website. Presentation materials and a replay of the call will also be made available in the same section.
QuidelOrtho (Nasdaq: QDEL) released episode 59 of its Science Bytes podcast, focused on how the U.S. drug overdose crisis is evolving and implications for toxicology testing. The episode, hosted by Josh Casey with guest Vonda McAllister, draws on new guidance from the Association for Diagnostics and Laboratory Medicine (ADLM).
Key points include three consecutive years of declining U.S. overdose deaths in 2025, persistent risks from counterfeit fentanyl-laced pills, rising polysubstance use, and emerging synthetic opioids such as nitazenes that can evade routine screening. The discussion stresses closer collaboration between laboratories and emergency departments and highlights laboratories’ role in test selection, result interpretation and supporting timely patient care decisions.